BioNTech SE (BNTX)

261.09
+13.41(+5.41%)
After Hours
261.70
+0.61(+0.23%)
- Real-time Data
  • Volume:
    1,994,368
  • Bid/Ask:
    260.10/261.79
  • Day's Range:
    245.03 - 261.13

BNTX Overview

Prev. Close
247.68
Day's Range
245.03-261.13
Revenue
8.98B
Open
245.34
52 wk Range
75.47-462.56
EPS
18.96
Volume
1,994,368
Market Cap
59.82B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
4,325,595
P/E Ratio
13.06
Beta
-
1-Year Change
163.24%
Shares Outstanding
241,521,065
Next Earnings Date
09 Nov 2021
What is your sentiment on BioNTech SE?
or
Market is currently closed. Voting is open during market hours.

BioNTech SE News

BioNTech SE Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyNeutralBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuySellStrong Buy
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Buy

BioNTech SE Company Profile

BioNTech SE Company Profile

Employees
2500

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Read More
  • WHO asks wealthy nations to hold off on Covid vaccine boosters at least through SeptemberPUBLISHED WED, AUG 4 20219:51 AM EDTUPDATED WED, AUG 4 202112:10 PM EDT
    0
    • Big buy now!
      2
      • Good news FDA had authorised extra dose vaccine!
        2
        • Not quite! Authorisation is restricted to the severely immunocompromised
          0
      • Buy?
        0
        • 3rd fose covid vaccine
          0
          • latest news. FDA reported to give full approval of Pfizer covid vaccine by Labor Day.
            0
            • Could this stock reac $1000?
              1
              • 250?
                0
                • Saving the world. Moreover, Still very bullish, indicators: Ichimoku, MFI, OBV, MA, etc. Good week. VIX = minimums (1 Y). Have a nice week!
                  0
                  • funny how some of these companies floated just before the crash...
                    2
                    • 200 euros tonight
                      0
                      • Any prediction for tommorow?
                        0
                        • Thanks you management services. Bullish
                          0
                          • Any idea why price of Pfizer is dropping but BioNTech is rising
                            0
                            • Could be sale deals in europe for vaccines but since pfizer gives high antibodies as reported in the news yesterday it should go up again this coming month.
                              0
                          • target 130 💪🏼
                            0
                            • 135
                              0
                          • vaccine is not working
                            8
                            • Vaccine is working as I know !?
                              0
                            • András Csath yeah It is working. Benny is just manipulating mate
                              0
                            • Your education isn't working
                              0
                          • Any idea why the price is dropping everyday?
                            0
                            • Possibly because of alergic reactions to the vaccine shown by approx 10 patients. Alternatively the new variant in UK is scaring people that the vaccine will no longer work
                              0
                            • No idea. I am asking this question myself. And all other values going up. Guess speculation phase sith vaccine has reached its limits
                              0
                            • Definitely profit taken. No other better news after approval , same as Moderna.
                              0
                          • BioNTech Says Can Make Mutation-Beating Vaccine In 6 Weeks Covid-19 Vaccine: "Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," said Ugur Sahin. https://www.ndtv.com/world-news/biontech-says-can-make-mutation-beating-coronavirus-vaccine-in-six-weeks-news-agency-afp-2342027
                            0
                            • Any ideas on price?
                              0
                              • Not Bad. It could fall somewhere between 104-106 in short term. But profitable in long run. (Not an investment advice)
                                0
                              • Good for long term. ❤️
                                0
                              • Goood for you ..
                                0
                            • https://www.nzherald.co.nz/world/covid-19-coronavirus-oxford-vaccine-will-be-ready-by-christmas-says-professor-leading-the-project/N5VKSFNULMSXMFITODAWLQV3SU/
                              0
                              • Hmmmmmm🤔Data looks strong to me. 150 soon
                                0
                                • Aged like milk.
                                  0
                                • This is the Juice
                                  0
                                • This is the Juice
                                  0
                              • -8% speaks volumes about the apparent vaccine lol
                                0
                                • If the vaccine is approved, what value do you think the share price will be?Any thougts....
                                  0
                                  • Pfizer 🙏❤️$80.00
                                    0
                                • What’s wrong, everyday drop
                                  0
                                  • Buy or sell? Going down
                                    0
                                    • if you didn't buy it so far, very good time to buy I would say. if you already have it wait till October / November
                                      2
                                    • buy
                                      0
                                    • buy
                                      0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.